Evidence map›Paper›PMID 40996677›Full record

ArticleDiscover oncology2025

Identification of immunosuppressive CD4

Chuxuan Wang, Lianchi Li, Yingrui Lou, Lan Zhang, Feifei Tian, Taoyou Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chuxuan Wang *School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China.
Lianchi Li *Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.
Yingrui LouSchool of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China.
Lan ZhangSchool of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China. zhanglanx_9@126.com.
Feifei TianSchool of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China. tulwar@home.swjtu.edu.cn.
Taoyou ZhouCenter of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China. marshelztyhx@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCD4

methodsWe analyzed single-cell RNA sequencing (scRNA-seq) data from 16 HCC patients (GSE149614). Cell types were annotated based on cluster-specific differentially expressed genes (DEGs), utilizing the SingleR and PISCES for automated cell type assignment, with reference to established markers from previous studies. Metabolic reprogramming, transcriptional networks, and intercellular communication were assessed via GSVA, SCENIC, and CellChat. A prognostic model integrating TCGA-LIHC and validated in GSE109211 was developed using LASSO Cox regression. Molecular docking and dynamics simulations evaluated the therapeutic potential of prioritized targets.

resultsThis study identifies SPP1

conclusionsOur findings establish SPP1

Indexed as

CD4+ t cellsHepatocellular carcinomaImmunosuppressionPrognostic modelscRNA-Seq

Identifiers

PMID40996677
PMCPMC12463779

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.